Aspen Re looks to casualty for Asia growth
September 8 2022 by Nick Ferguson
-
Emerging Asia may benefit from US tariffs as China suffers: Swiss Re’s Haegeli
- November 21
Tariffs, taxes, and a decrease in trade could be a tipping point for the wider industry as there are many uncertainties around future US presidential decisions, said the reinsurer's group chief economist.
-
Japan’s big three post US$8bn windfall from strategic holdings unwind
- November 20
The major insurance groups also showed significant improvements in H1 CORs as they benefitted from benign loss environment at home and overseas and robust premium growth.
-
Modellers step up efforts on flood models amid rising secondary peril risk in APAC
- November 18
Verisk and Moody’s RMS indicate they are listening to the concerns of the market and have laid out plans to “close the gap”.
-
US exposures, climate change, pricing challenges weigh on APAC casualty underwriters
- November 15
The casualty market faces challenges in predicting risks due to global interconnectedness and emerging threats like PFAS and cyber.
-
BHSI | Managing non-Asian exposure in long-tail lines
While US-exposed business can look attractive to Asian carriers, managing the volatility around the long-term results and the ability to model those losses are crucial, say BHSI’s Marc Breuil and Marcus Portbury.
-
Sedgwick | To Handle CAT Claims Well, Multi-Step Preparation is Key
When it comes to risk, it’s not a matter of “if” it’s a matter of “when” an event will occur.
-
HSBC Asset Management | Is it time to relook at Asian currency bonds?
With diversification and performance high on investors’ agendas, it seems a good time for global portfolios to revive allocations in Asian local currency bonds – including Hong Kong dollar (HKD) bonds.
-
PineBridge Investments | Why Asian insurers are exploring private credit and CLOs
The recent rollout of risk-based capital regimes across Asia calls for a closer alignment between insurers’ assets and liabilities. We explore potential ways to maintain a healthy investment yield and robust returns on regulatory capital.
